Mackenzie Financial’s Coherus Oncology CHRS Stock Holding History

Mackenzie Financial’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-49,283	Closed	-$337K	–	1528
2023 Q1	$337K	Sell	49,283 -25,800	-34%	-$200K	﹤0.01%	1149
2022 Q4	$595K	Buy	75,083 +27,393	+57%	+$211K	﹤0.01%	876
2022 Q3	$458K	Sell	47,690 -8	-0%	-$81	﹤0.01%	958
2022 Q2	$345K	Buy	47,698 +14,027	+42%	+$122K	﹤0.01%	1038
2022 Q1	$435K	Buy	33,671 +1,509	+5%	+$19.2K	﹤0.01%	1021
2021 Q4	$513K	Buy	+32,162	New	+$562K	﹤0.01%	999

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Mackenzie Financial's CHRS Position: Q2 2023 in Review

Mackenzie Financial sold out of Coherus Oncology (CHRS) in Q2 2023, closing a stake of 49,283 shares — an estimated $337K sold.

Mackenzie Financial first reported a position in CHRS in Q4 2021 and held it in 6 quarters. The position peaked at $595K in Q4 2022. 161 funds tracked by Wall St. Rank hold CHRS as of Q2 2023.

Mackenzie Financial reported no remaining Coherus Oncology position as of Q2 2023 after selling out during the quarter.
Mackenzie Financial sold 49,283 Coherus Oncology shares in Q2 2023, an estimated $337K.
Mackenzie Financial first reported a position in Coherus Oncology in Q4 2021 and held it in 6 quarters.
Mackenzie Financial's Coherus Oncology position peaked at $595K in Q4 2022.
161 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2023.

Based on Mackenzie Financial's 13F filing for Q2 2023, filed 3 Aug 2023.